DR info

臨床試験数 : 19 / 薬物数 : 22 - (DrugBank : 7) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 63

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

Bleomycin
   Fujino Akihiro
      2016   -   JPRN-jRCTs031180265   Japan;
CERC-006
   Cerecor Inc
      2021   Phase 1   NCT04994002   United States;
Indocyanine green
   Aitaro Takimoto
      2017   Phase 2   JPRN-jRCTs041190036   Japan;
   Nagoya University Graduate School ofMedicine
      2017   -   JPRN-UMIN000025845   Japan;
L04AA10
   CHRU TOURS
      2019   Phase 2   EUCTR2019-001530-33-FR   France;
MRI
   University Hospital, Lille
      2018   Phase 2   NCT03243019   France;
OK432
   Richard JH Smith
      1998   Phase 4   NCT03427619   United States;
Oral sirolimus
   Children's Hospital of Fudan University
      2021   Phase 4   NCT04921722   China;
PTX-022
   Palvella Therapeutics, Inc.
      2021   Phase 2   NCT05050149   United States;
Percutaneous sirolimus
   Children's Hospital of Fudan University
      2021   Phase 4   NCT04921722   China;
Picibanil
   University of Iowa
      2000   Phase 2/Phase 3   NCT00010452   United States;
Propranolol
   University of Tokyo
      2012   Phase 2   JPRN-UMIN000008498   Japan;
Rapamycin dosage
   University Hospital, Lille
      2018   Phase 2   NCT03243019   France;
Selenium
   Medical College of Wisconsin
      2010   Phase 1   NCT01212965   United States;
Sildenafil
   Beijing Children's Hospital
      2014   -   ChiCTR-OPC-16008702   China;
Sildenafil 20 mg tablets
   Stanford University
      2015   Phase 2   NCT02335242   United States;
Sirolimus
   Children's Hospital Medical Center, Cincinnati
      2009   Phase 2   NCT00975819   United States;
   Gifu University
      2017   -   JPRN-UMIN000030522   Japan;
   Gifu University Hospital
      2020   Phase 3   JPRN-UMIN000038973   Japan;
   Medical University of South Carolina
      2021   Phase 2   NCT04861064   United States;
Sirolimus 0, crème
   CHRU TOURS
      2019   Phase 2   EUCTR2018-001359-11-FR   France;
Sirolimus 1mg/mL
   CHRU TOURS
      2019   Phase 2   EUCTR2019-001530-33-FR   France;
Sirolimus Oral Liquid Product 1mg/mL
   University Hospital, Tours
      2020   Phase 2   NCT04128722   France;
Topical Sirolimus
   University Hospital, Tours
      2019   Phase 2   NCT03972592   France;
Topical Vehicle
   University Hospital, Tours
      2019   Phase 2   NCT03972592   France;
VT30
   Venthera, Inc., a BridgeBio company
      2020   Phase 1/Phase 2   NCT04409145   United States;
Water
   Fujino Akihiro
      2016   -   JPRN-jRCTs031180265   Japan;